Table 2.
Baseline demographics and tumoral characteristics.
| Characteristics | PVA (n = 48) | ME (n = 32) | P value |
|---|---|---|---|
| Age (years) | 61 ± 8.3 | 60.4 ± 9.6 | 0.75 |
| Gender (male) | 58.3% | 81.3% | 0.06 |
| Caucasians (%) | 93% | 99% | 0.28 |
| Body mass index (kg/m2) | 26.1 ± 4.2 | 26.4 ± 4.4 | 0.76 |
| HCV positive (%) | 82.2% | 74.2% | 0.58 |
| HCVRNA PCR qualit. (%) | 90.0% | 81.8% | 0.60 |
| Alcohol induced cirrhosis (%) | 34.8% | 34.5% | 1.0 |
| BCLC (%) | |||
| A | 36.0 | 25.0 | 0.36 |
| B | 60.0 | 75.0 | |
| C | 3.3 | 0 | |
| Child-Pugh (%) | |||
| A | 43.8 | 59.4 | 0.25 |
| B | 50.0 | 31.3 | |
| C | 6.3 | 9.4 | |
| MELD | 12.4 | 14.3 | 0.12 |
| Performance status (0) | 93.8% | 84.4% | 0.26 |
| Aspartate transaminase (U/L) | 36.6 | 37.6 | 0.85 |
| Alanine transaminase (U/L) | 62.3 | 79.7 | 0.85 |
| Gamma-glutamyl transferase (U/L) | 134.9 | 117.2 | 0.48 |
| Platelets (×1000/UL) | 100.7 | 115.6 | 0.25 |
| Prothrombin time (%) | 72.9 | 76.9 | 0.26 |
| Albumin (U/L) | 3.25 | 3.46 | 0.22 |
| Total bilirubin (mg/dL) | 1.49 | 1.2 | 0.08 |
| Alpha-fetoprotein (ng/mL) | (44) 2747 | (28) 1027 | 0.22 |
| Creatinine | 0.93 | 0.95 | 0.72 |
| CTMD | 65.0% | 51.0% | 0.34 |
| Tumor size (cm) | 4.7 | 5.4 | 0.11 |
| Number of tumors | |||
| 1 | 66.7% | 25.0% | 0.49 |
| <3 | 29.2% | 62.5% | 0.48 |
| ≥3 | 4.2% | 12.5% | 0.48 |
| Number of transarterial embolizations | 2.3 | 2.1 | 0.19 |
PVA: polyvinyl alcohol; ME: microspheres; HCV, hepatitis C virus; HCVRNA PCR qualit.: C-reactive protein qualitative RNA hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; MELD: Model for End-Stage Liver Disease; CTMD: computed tomography multidetector.